About CorMedix (NYSEAMERICAN:CRMD)
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E Ratio-0.508196721311475
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-318.95%
Return on Assets-227.65%
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) announced its earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.08. The biotechnology company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.05 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View CorMedix's Earnings History.
When will CorMedix make its next earnings announcement?
Where is CorMedix's stock going? Where will CorMedix's stock price be in 2018?
3 brokerages have issued twelve-month price targets for CorMedix's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate CorMedix's share price to reach $3.50 in the next year. View Analyst Ratings for CorMedix.
Are investors shorting CorMedix?
CorMedix saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,692,803 shares, an increase of 8.3% from the January 12th total of 4,332,544 shares. Based on an average daily trading volume, of 651,504 shares, the short-interest ratio is presently 7.2 days. Approximately 7.6% of the company's shares are sold short.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include OptiBiotix Health (OPTI), VIVUS (VVUS), Electromed (ELMD), pSivida (PSDV), SCYNEXIS (SCYX), Amryt Pharma (AMYT), Ocera Therapeutics (OCRX), Futura Medical (FUM), Capricor Therapeutics (CAPR), Opiant Pharmaceuticals (OPNT), Concordia International (CXR), Actinium Pharmaceuticals (ATNM), Reshape Lifesciences (RSLS), CytRx (CYTR), Avinger (AVGR), BIOLASE (BIOL), Immutep (IMMP) and Proteon Therapeutics (PRTO).
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Myron M. Kaplan, Chairman of the Board (Age 70)
- Randy Milby, Chief Executive Officer, Director (Age 61)
- Robert W. Cook, Chief Financial Officer (Age 60)
- Antony E. Pfaffle M.D., Chief Scientific Officer, Director (Age 51)
- Khoso Baluch, Director
- Gary A. Gelbfish M.D., Director (Age 54)
- Mehmood Khan M.D., Director (Age 58)
- Janet M. Dillione, Independent Director (Age 55)
- Matthew P. Duffy, Independent Director (Age 52)
Who owns CorMedix stock?
CorMedix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Spinnaker Capital LLC (0.60%) and Virtu Financial LLC (0.34%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew Duffy, Mehmood Khan, Myron Kaplan, Robert W Cook, Steven W Lefkowitz and Taunia Markvicka. View Institutional Ownership Trends for CorMedix.
Who bought CorMedix stock? Who is buying CorMedix stock?
CorMedix's stock was bought by a variety of institutional investors in the last quarter, including Spinnaker Capital LLC and Virtu Financial LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook, Steven W Lefkowitz and Taunia Markvicka. View Insider Buying and Selling for CorMedix.
How do I buy CorMedix stock?
Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CorMedix stock can currently be purchased for approximately $0.32.
How big of a company is CorMedix?
CorMedix has a market capitalization of $25.91 million.
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (CRMD)MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
CorMedix (NYSEAMERICAN:CRMD) Earnings History and Estimates Chart
CorMedix (NYSEAMERICAN CRMD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.16)||($0.14)||$0.15 million||$0.14 million||View||N/A|
|5/10/2017||Q1 2017||($0.15)||($0.19)||$0.09 million||$0.04 million||View||N/A|
|3/16/2017||Q4 2016||($0.22)||($0.16)||$0.06 million||$0.12 million||View||N/A|
|11/9/2016||Q3 2016||($0.15)||($0.23)||$0.05 million||$0.04 million||View||N/A|
|8/5/2016||Q216||($0.11)||($0.13)||$119.97 million||$16.51 million||View||N/A|
|5/10/2016||Q1||($0.09)||($0.12)||$0.11 million||$0.04 million||View||N/A|
|3/16/2016||Q4 2015||($0.16)||($0.11)||$0.07 million||$0.02 million||View||N/A|
|11/12/2015||Q3||($0.13)||($0.14)||$0.12 million||$0.04 million||View||Listen|
|8/6/2015||Q2 2015||($0.13)||($0.13)||$0.08 million||$0.12 million||View||N/A|
|5/7/2015||Q1 2015||($0.10)||($0.23)||$0.07 million||$0.03 million||View||N/A|
|3/12/2015||Q4 2014||($0.12)||($0.09)||$0.08 million||$0.09 million||View||N/A|
|11/13/2014||Q3 2014||($0.09)||($0.09)||$0.08 million||$0.05 million||View||N/A|
|8/14/2014||Q2 2014||($0.13)||($0.26)||$0.02 million||$0.04 million||View||N/A|
|5/15/2014||Q1 2014||($0.16)||$0.01 million||View||N/A|
CorMedix (NYSEAMERICAN:CRMD) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for CorMedix (NYSEAMERICAN:CRMD)
No dividend announcements for this company have been tracked by MarketBeat.com
CorMedix (NYSEAMERICAN CRMD) Insider Trading and Institutional Ownership History
CorMedix (NYSEAMERICAN CRMD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/12/2017||Jr. John L Armstrong||VP||Buy||20,833||$0.48||$9,999.84||20,833|| |
|12/12/2017||Khoso Baluch||CEO||Buy||104,166||$0.48||$49,999.68||225,373|| |
|12/12/2017||Robert W Cook||CFO||Buy||52,083||$0.48||$24,999.84||102,083|| |
|12/12/2017||Steven W Lefkowitz||Director||Buy||135,416||$0.48||$64,999.68|| |
|8/18/2017||Khoso Baluch||CEO||Buy||36,207||$0.42||$15,206.94||121,207|| |
|8/18/2017||Mehmood Khan||Director||Buy||400,000||$0.39||$156,000.00||50,000|| |
|8/17/2017||Myron Kaplan||Director||Buy||80,000||$0.40||$32,000.00||180,000|| |
|8/14/2017||Myron Kaplan||Director||Buy||50,000||$0.35||$17,500.00||100,000|| |
|5/30/2017||Cora M Tellez||Director||Buy||7,550||$0.42||$3,171.00||182,371|| |
|5/17/2017||Khoso Baluch||CEO||Buy||75,000||$0.48||$36,000.00||85,000|| |
|5/16/2017||Cora M Tellez||Director||Buy||50,000||$0.48||$24,000.00||174,821|| |
|5/15/2017||Janet Dillione||Director||Buy||21,231||$0.48||$10,190.88||39,969|| |
|5/15/2017||Robert W Cook||CFO||Buy||50,000||$0.50||$25,000.00||50,000|| |
|5/1/2017||Cora M Tellez||Director||Buy||4,800||$0.66||$3,168.00||124,821|| |
|3/30/2017||Cora M Tellez||Director||Buy||1,950||$1.66||$3,237.00||120,021|| |
|2/28/2017||Cora M Tellez||Director||Buy||1,540||$2.10||$3,234.00||118,071|| |
|2/7/2017||Antony Pfaffle||Insider||Sell||10,000||$2.00||$20,000.00||10,000|| |
|1/30/2017||Cora M Tellez||Director||Buy||1,780||$1.79||$3,186.20||116,531|| |
|12/30/2016||Cora M Tellez||Director||Buy||1,990||$1.58||$3,144.20||114,751|| |
|12/9/2016||Khoso Baluch||CEO||Buy||10,000||$1.77||$17,700.00||10,000|| |
|11/30/2016||Cora M Tellez||Director||Buy||1,800||$1.80||$3,240.00||112,761|| |
|10/31/2016||Cora M Tellez||Director||Buy||1,475||$2.15||$3,171.25||110,961|| |
|10/21/2016||Antony Pfaffle||Insider||Sell||20,000||$2.23||$44,600.00||20,000|| |
|9/22/2016||Janet Dillione||Director||Buy||15,000||$2.66||$39,900.00||15,000|| |
|8/25/2016||Taunia Markvicka||Director||Buy||18,600||$1.65||$30,690.00||22,600|| |
|8/19/2016||Cora M Tellez||Director||Buy||12,500||$1.73||$21,625.00||109,486|| |
|6/21/2016||Antony Pfaffle||Insider||Sell||29,657||$2.14||$63,465.98||10,000|| |
|6/20/2016||Antony Pfaffle||Insider||Sell||10,000||$2.16||$21,600.00||10,000|| |
|6/15/2016||Antony Pfaffle||Insider||Sell||4,900||$2.21||$10,829.00||4,900|| |
|6/13/2016||Antony Pfaffle||Insider||Sell||5,443||$2.27||$12,355.61||5,000|| |
|6/9/2016||Antony Pfaffle||Insider||Sell||10,000||$2.38||$23,800.00||10,000|| |
|6/8/2016||Janet Dillione||Director||Buy||3,738||$2.67||$9,980.46||18,738|| |
|6/3/2016||Matthew Duffy||Director||Sell||46,106||$2.73||$125,869.38||28,571|| |
|5/31/2016||Steven W Lefkowitz||Director||Sell||50,000||$2.88||$144,000.00||159,599|| |
|5/25/2016||Cora M Tellez||Director||Buy||8,600||$2.90||$24,940.00||96,986|| |
|5/24/2016||Antony Pfaffle||Insider||Sell||12,700||$2.73||$34,671.00||12,700|| |
|5/24/2016||Antony Pfaffle||Insider||Sell||12,700||$2.73||$34,671.00||12,700|| |
|5/23/2016||Antony Pfaffle||Insider||Sell||15,000||$2.89||$43,350.00||10,000|| |
|5/23/2016||Steven W Lefkowitz||Director||Sell||30,000||$2.93||$87,900.00||132,525|| |
|5/19/2016||Antony Pfaffle||Insider||Sell||12,300||$2.82||$34,686.00||12,300|| |
|5/16/2016||Antony Pfaffle||Insider||Sell||60,000||$2.68||$160,800.00||60,000|| |
|6/30/2015||Randy Milby||CEO||Buy||1,610||$3.88||$6,246.80|| |
|6/23/2015||Taunia Markvicka||Director||Buy||4,000||$4.81||$19,240.00|| |
|6/15/2015||Randy Milby||CEO||Buy||1,245||$5.02||$6,249.90|| |
|6/4/2015||Matthew Duffy||Director||Sell||30,000||$6.48||$194,400.00|| |
|5/29/2015||Randy Milby||CEO||Buy||1,026||$6.09||$6,248.34|| |
|2/27/2015||Randy Milby||CEO||Buy||1,211||$5.16||$6,248.76|| |
|2/13/2015||Randy Milby||CEO||Buy||1,911||$3.27||$6,248.97|| |
|1/30/2015||Randy Milby||CEO||Buy||2,016||$3.10||$6,249.60|| |
|12/15/2014||Randy Milby||CEO||Buy||4,734||$1.32||$6,248.88|| |
|11/28/2014||Randy Milby||CEO||Buy||4,464||$1.40||$6,249.60|| |
|11/14/2014||Cora M Tellez||Director||Buy||11,086||$1.52||$16,850.72|| |
|11/14/2014||Randy Milby||CEO||Buy||4,111||$1.52||$6,248.72|| |
|10/31/2014||Randy Milby||CEO||Buy||3,434||$1.82||$6,249.88|| |
|9/30/2014||Randy Milby||CEO||Buy||3,324||$1.88||$6,249.12|| |
|9/15/2014||Randy Milby||CEO||Buy||3,654||$1.71||$6,248.34|| |
|8/29/2014||Randy Milby||CEO||Buy||3,125||$2.00||$6,250.00|| |
|8/15/2014||Randy Milby||CEO||Buy||3,140||$1.99||$6,248.60|| |
|7/31/2014||Randy Milby||CEO||Buy||6,250||$2.00||$12,500.00|| |
|6/30/2014||Randy Milby||CEO||Buy||2,732||$1.83||$4,999.56|| |
|12/13/2013||Steven W Lefkowitz||Insider||Buy||18,000||$0.78||$14,040.00|| |
CorMedix (NYSEAMERICAN CRMD) News Headlines
|Why CorMedix Inc. (CRMD) Shares Took a Nosedive Today|
finance.yahoo.com - February 20 at 5:50 PM
|CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy Analysis|
finance.yahoo.com - February 20 at 8:13 AM
|CorMedix Inc. (CRMD) Short Interest Update|
www.americanbankingnews.com - February 9 at 8:28 PM
|Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics|
www.bizjournals.com - February 9 at 9:21 AM
|CorMedix Inc. (CRMD) Short Interest Up 8.3% in January|
www.americanbankingnews.com - January 24 at 6:10 PM
|CorMedix Inc. (CRMD) Short Interest Down 10.2% in December|
www.americanbankingnews.com - January 11 at 2:36 AM
|ETFs with exposure to CorMedix, Inc. : January 1, 2018|
finance.yahoo.com - January 1 at 5:12 PM
|CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017|
finance.yahoo.com - December 28 at 1:16 PM
|Short Interest in CorMedix Inc. (CRMD) Increases By 20.4%|
www.americanbankingnews.com - December 27 at 6:38 PM
|ETFs with exposure to CorMedix, Inc. : December 19, 2017|
finance.yahoo.com - December 19 at 5:16 PM
|CorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 Shares|
www.americanbankingnews.com - December 14 at 6:50 PM
|Khoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) Stock|
www.americanbankingnews.com - December 14 at 6:28 PM
|CorMedix Inc. (CRMD) Director Steven W. Lefkowitz Acquires 135,416 Shares|
www.americanbankingnews.com - December 14 at 6:26 PM
|ETFs with exposure to CorMedix, Inc. : December 7, 2017|
finance.yahoo.com - December 7 at 5:43 PM
|CorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases|
finance.yahoo.com - December 5 at 10:14 AM
|CorMedix Inc (CRMD): Should The Recent EPS Drop Worry You?|
finance.yahoo.com - December 4 at 5:16 PM
|CorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology|
finance.yahoo.com - November 29 at 9:37 AM
|Short Interest in CorMedix Inc. (CRMD) Grows By 21.6%|
www.americanbankingnews.com - November 27 at 7:48 PM
|CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team|
finance.yahoo.com - November 20 at 6:34 PM
CorMedix (NYSEAMERICAN:CRMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CorMedix (NYSEAMERICAN:CRMD) Income Statement, Balance Sheet and Cash Flow Statement
CorMedix (NYSEAMERICAN CRMD) Stock Chart for Friday, February, 23, 2018